BioNTech (BNTX) vs Kymera Therapeutics (KYMR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kymera Therapeutics (KYMR) has outperformed BioNTech (BNTX) over the past year, gaining 74.6% versus a loss of 15.3%. Over five years, KYMR leads with a +114.4% price change compared with -76.7% for BNTX. BioNTech is the larger company by market cap ($20.07 billion vs $9.84 billion), about 2.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTX | KYMR |
|---|---|---|
| Share price | $80.96 | $115.31 |
| Market cap | $20.07B | $9.84B |
| 1-day change | -0.52% | -3.42% |
| YTD return | -14.96% | +48.19% |
| 1-year return | -15.30% | +74.61% |
| 5-year return | -76.74% | +114.37% |
| EPS (TTM) | $-6.83 | $-3.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $39.21M |
| Revenue growth (YoY) | — | -16.70% |
| Net income (latest FY) | — | $-311.35M |
| Gross margin | — | 0.00% |
| Operating margin | — | -891.07% |
| Net margin | — | -794.04% |
| 52-week high | $124.00 | $142.92 |
| 52-week low | $79.52 | $63.69 |
| Distance from 52-week high | -34.71% | -19.32% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +38.51% | +25.94% |
| Average volume | 1.08M | 852.46K |
| Shares outstanding | 247.93M | 85.37M |
| Employees | 7,807 | 285 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BioNTech is about 2.0 times larger than Kymera Therapeutics by market value ($20.07B vs $9.84B).
- KYMR has outperformed BNTX by 89.9 percentage points over the past year.
About BioNTech
BNTX stock →BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees
About Kymera Therapeutics
KYMR stock →Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 285 employees
BNTX vs KYMR FAQ
Which is bigger, BioNTech or Kymera Therapeutics?
BioNTech (BNTX) is larger, with a market capitalization of $20.07B compared with $9.84B for Kymera Therapeutics (KYMR).
Which stock has performed better over the past year, BNTX or KYMR?
KYMR returned +74.61% over the past 12 months, compared with -15.30% for BNTX (price return, excluding dividends). Past performance does not predict future results.
Are BioNTech and Kymera Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.